Table 1 Combination oral contraceptive use among premenopausal WISH participants, by brand name and crossclassified by pill content and potency

From: Hormonal content and potency of oral contraceptives and breast cancer risk among young women

 

Low progestin/high oestrogen potency

Low progestin/low oestrogen potency

High progestin/low oestrogen potency

Low progestin/high oestrogen potency

Progestin

Mestranol

Ethinyl oestradiol

Ethinyl oestradiol

Mestranol

Mestranol

Ethinyl oestradiol

Chlormadinone acetate

      

Dimethisterone

      

Ethynodiol diacetate

  

Demulen 1/35a (1/35)

Ovulena (1/100)

Demulen 1/35a (1/35)

Ovulena (1/100)

   

Demulen 1/50a (1/50)

 

Demulen 1/50a (1/50)

 

Medroxyprogesterone acetate

  

Provesta (10/50)

 

Provesta (10/50)

 

Norethynodrel

   

Enovid 10 mga (9.85/150)

 

Enovid 10 mga (9.85/150)

Norethindrone

Genora 1/50a (1/50)

Brevicon (0.5/35)

 

Ortho-Novum 10 mga

 

Ortho-Novum 10 mga

 

Norinyl 1/50 (1/50)

Modicon (0.5/35)

 

(10/60)

 

(10/60)

 

Ortho-Novum 1/50

Nelova 1/35ea (1/35)

 

Norinyl 10 mg a (10/60)

 

Norinyl 10 mg a (10/60)

 

(1/50)

Norinyl 1/35 (1/35)

    
  

Tri-norinyl (0.5 : 1 : 0.5/35)

    
  

ORF 1557-BE a (0.5/35)

    
  

ORF 1557-BF a (1/35)

    
  

Ortho-novum 1/35 (1/35)

    
  

Ortho-novum 10/11 (0.5 : 1/35)

    
  

Ortho-novum 7/7/7 (0.5 : 0.75 : 1/35)

    
  

Ovcon 35 (0.4/35)

    

Norethindrone acetate

 

Loestrin 1.5/30 (1.5/30)

 

Norlestrin 1/50a (1/50)

Ovral (0.5/50)

 
  

Loestrin 1/20 (1/20)

 

Norlestrin 2.5/50 a (2.5/50)

  
  

Norlestrin var red a (1/20)

 

Norlestrin low a (0.5/50)

  
  

Zorane 1.5/30a (1.5/30)

 

Norlestrin var black a

  
  

Zorane 1/20a (1/20)

 

(2/40)

  

Norgestrel

 

Lo/Ovral (0.3/30)

Ovral (0.5/50)

   
  

Ovral blue a (0.15/30)

    
  

Ovral brown a (0.15/15)

    

Levonorgestrel

 

Levlen (0.15/35)

    
  

Nordette (0.15/30)

    
  

Tri-levlen (0.05 : 0.075 : 0.125/30 : 40 : 30)

    
  

Triphasil (0.05 : 0.075 : 0.125/30 :40 : 30)

    
  1. aOral contraceptives no longer marketed in the United States (not listed in the 2002 Physician's Desk Reference).
  2. Note: Progestin (mg) and oestrogen dose (μg) is indicated after each oral contraceptive brand name in parentheses. Italicized brand names were added to the potency scheme based on progestin and oestrogen content as evaluated by the authors.